UCLB spinout Freeline Closes $120 Million Series C Financing Round
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, announced the closing of a $120 million extended Series C financing. The financing augments Syncona’s previously announced Series C investment in Freeline of $40 million (£30.6 million) with an additional $80 million (£61.2 million) of new capital. The round was led by Novo Holdings A/S, Eventide Asset Management and Wellington Management Company, with additional participation from Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.
Read the full announcement on the Freeline website.